Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $26
Relay Therapeutics, Inc.
Relay Therapeutics, Inc. RLAY | 0.00 |
Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ:
RLAY) with a Market Outperform and raises the price target from $21 to $26.
